Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say

A Johnson & Johnson citizen petition lays out the company’s case for individual non-proprietary names for biologics and each of their biosimilars, citing the risk of inappropriate substitution.